# PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

> **NCT00472043** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 66 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** PDT with Metvix 160 mg/g cream
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00472043
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10-01
- **Primary completion:** 2002-09-30
- **Final completion:** 2002-09-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472043, "PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00472043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*